Different Doses of Naronapride vs. Placebo in Gastroparesis

ClinicalTrials.gov ID: NCT05621811

Public ClinicalTrials.gov record NCT05621811. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 20, 2026, 4:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Double-blind, Randomised, Placebo-controlled, Dose-finding Phase IIb Trial to Evaluate the Efficacy, Safety, and Tolerability of a 12-week-treatment With Naronapride in Adult Participants With at Least Moderate Idiopathic or Diabetic Gastroparesis

Study identification

NCT ID: NCT05621811
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Dr. Falk Pharma GmbH; Industry
Enrollment: 328 participants

Conditions and interventions

Conditions

Gastroparesis

Interventions

Naronapride Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 2, 2023
Primary completion: Aug 11, 2025
Completion: Sep 3, 2025
Last update posted: Apr 14, 2026

2023 – 2025

United States locations

U.S. sites: 21
U.S. states: 11
U.S. cities: 19

Facility	City	State	ZIP	Site status
Dr Falk Investigational Site	Chula Vista	California	91910	—
Dr Falk Investigational Site	Lomita	California	90717	—
Dr Falk Investigational Site	Clearwater	Florida	33756	—
Dr Falk Investigational Site	Doral	Florida	33126	—
Dr Falk Investigational Site	Hollywood	Florida	33021	—
Dr Falk Investigational Site	Maitland	Florida	32751	—
Dr Falk Investigational Site	Miami	Florida	33144	—
Dr Falk Investigational Site	Miami	Florida	33183	—
Dr Falk Investigational Site	Viera	Florida	32940	—
Dr Falk Investigational Site	Topeka	Kansas	66606	—
Dr Falk Investigational Site	Crestview Hills	Kentucky	41017	—
Dr Falk Investigational Site	Houma	Louisiana	70363	—
Dr Falk Investigational Site	Marrero	Louisiana	70072	—
Dr Falk Investigational Site	Flint	Michigan	48439	—
Dr Falk Investigational Site	Flint	Michigan	48503	—
Dr Falk Investigational Site	New York	New York	10033	—
Dr Falk Investigational Site	Tulsa	Oklahoma	74104	—
Dr Falk Investigational Site	Philadelphia	Pennsylvania	19087	—
Dr Falk Investigational Site	Cordova	Tennessee	38018	—
Dr Falk Investigational Site	Nashville	Tennessee	37211	—
Dr Falk Investigational Site	Harlingen	Texas	78550	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05621811, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 14, 2026 · Synced May 20, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05621811 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →